SEC Comment Letter for Hoth Therapeutics, Inc. (HOTH) (CIK 0001711786) (RKTO) — Sep 10, 2019
Hoth Therapeutics, Inc. (HOTH) (CIK 0001711786)
Date: Sept. 10, 2019 · CIK: 0001711786 · Accession: 0000000000-19-013327
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233563
Letter
September 6, 2019 Robb Knie Chief Executive Officer Hoth Therapeutics, Inc. 1 Rockefeller Plaza, Suite 1039 New York, NY 10020 Re:Hoth Therapeutics, Inc. Registration Statement on Form S-1 Filed August 30, 2019 File No. 333-233563 Dear Mr. Knie: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Nazia J. Khan, Esq.
Show Raw Text
September 6, 2019
Robb Knie
Chief Executive Officer
Hoth Therapeutics, Inc.
1 Rockefeller Plaza, Suite 1039
New York, NY 10020
Re:Hoth Therapeutics, Inc.
Registration Statement on Form S-1
Filed August 30, 2019
File No. 333-233563
Dear Mr. Knie:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Nazia J. Khan, Esq.